Anti-Nectin-4 ADC Liquid Formulation to Limit Aggregation and Shedding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antibody-drug conjugates (ADCs) exhibit poor stability in liquid formulations, leading to drug shedding and aggregate formation during storage, necessitating lyophilized formulations which are not suitable for all administration routes.
Innovation Solution
A liquid formulation comprising an anti-Nectin-4 antibody-drug conjugate with specific buffer and auxiliary materials, including phosphate buffer, trehalose, and polysorbate 20, maintains stability and minimizes drug shedding and aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If ADCs are formulated as liquid formulations, then ease of administration is improved, but stability deteriorates leading to drug shedding and aggregate formation
Solution Approach 1:
The patent introduces multiple stabilizing agents as intermediaries to mediate between the liquid formulation environment and the ADC molecule. These include surfactants (polysorbate 20, polysorbate 80, or poloxamer 188) that prevent aggregation, sugars (trehalose, sucrose, or lactose) that stabilize protein structure, and amino acids (arginine, glycine, or histidine) that maintain solubility and prevent precipitation. These intermediaries protect the ADC from degradation while in liquid form, enabling both ease of administration and stability.
Solution Approach 2:
The patent systematically optimizes multiple formulation parameters to achieve stability in liquid form: controlling pH within specific ranges (6.0-8.0 preferably 6.5-7.5), adjusting ionic strength through buffer concentration (10-50 mM), controlling excipient concentrations (surfactant 0.01-0.5%, sugar 1-10%, amino acid 1-10%), and setting ADC concentration (1-50 mg/mL). These parameter changes transform the liquid formulation from an unstable state to a stable state that prevents drug shedding and aggregation while maintaining ease of administration.
2Loss of time
If ADCs are stored long-term in liquid formulations, then convenience is improved, but manufacturing precision deteriorates due to increased aggregation
Solution Approach 1:
The patent incorporates stabilizing agents into the formulation before storage, performing preliminary protective action. The surfactants, sugars, and amino acids are pre-added to the formulation to prevent aggregation and maintain stability during long-term storage. This preliminary stabilization allows the ADC to remain in liquid form for extended periods (months to years) without significant aggregation or drug shedding, thus improving both storage time and maintaining manufacturing precision.
3Reliability
If stabilizing agents are added to maintain ADC stability, then reliability is improved, but formulation complexity increases
Solution Approach 1:
The patent uses a systematic approach to parameter optimization, establishing specific concentration ranges for each component: buffer (10-50 mM), surfactant (0.01-0.5%), sugar (1-10%), amino acid (1-10%), and ADC (1-50 mg/mL). By defining these parameter ranges, the patent transforms a potentially complex formulation into a manageable system where stability is achieved through controlled variation of key parameters rather than arbitrary combinations of ingredients.
Solution Approach 2:
The patent employs excipients that serve multiple functions simultaneously. For example, trehalose acts as both a stabilizer and an osmotic agent; phosphate buffer provides both pH control and ionic strength adjustment; surfactants prevent both aggregation and adsorption to container surfaces. This multi-functionality reduces the need for additional separate agents, thereby improving reliability while limiting the increase in formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures stability of the anti-Nectin-4 antibody-drug conjugate, allowing for effective long-term storage with minimal protein aggregation and drug shedding, suitable for parenteral administration including intravenous use.
Implementation Method 1
the formulation comprises a buffer and an auxiliary material... maintains stability and minimizes drug shedding and aggregation
Implementation Method 2
the formulation comprises a buffer and an auxiliary material... minimizes drug shedding and aggregation
Implementation Method 3
the formulation comprises an anti-Nectin-4 antibody-drug conjugate with specific buffer and auxiliary materials, including phosphate buffer
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3C
AI summary
The present invention provides a preparation containing an anti-Nectin-4 Antibody-drug conjugate (ADC) and a use thereof. The preparation comprises an ADC, a buffering agent and an excipient. The anti-Nectin-4 ADC in the preparation exists stably, proteins do not aggregate after long-term storage, small molecule drugs are not prone to becoming detached, the osmotic pressure of the preparation is close to isotonic, and targeted therapy of Nectin-4 related diseases is facilitated.